nach oben

Acta Neurologica Belgica

Erschienen in:

08.07.2019 | Review article

Therapeutic approach to Lennox–Gastaut syndrome: a systematic review

verfasst von: Serena Borrelli, Riem El Tahry

Erschienen in: Acta Neurologica Belgica | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Lennox–Gastaut syndrome (LGS) is a rare, age-related syndrome, characterized by multiple seizure types, mental regression, and specific EEG abnormalities. It is one of the most challenging epilepsy: treatment is rarely effective and the final prognosis remains poor, despite the availability of several antiepileptic drugs, validated through well-designed, randomized, controlled trials. However, it is reasonable to consider non-medical treatments, such as surgery, after failure of two-to-three drugs. This review has as goal to describe systematically the different therapeutic options for LGS, including, not only recognized antiepileptic drugs, but also new oral drugs, immune therapy, diet, surgery, and neurostimulation techniques.

van Rijckevorsel K (2008) Treatment of Lennox–Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat 4(6):1001–1019CrossRefPubMedPubMedCentral

Arzimanoglou A et al (2009) Lennox–Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 8(1):82–93CrossRefPubMed

Crumrine PK (2002) Lennox–Gastaut syndrome. J Child Neurol 17(Suppl 1):S70–S75CrossRefPubMed

Vassella F et al (1978) Double-blind study on the anti-convulsive effect of phenobarbital and valproate in the Lennox syndrome. Schweiz Med Wochenschr 108(19):713–716PubMed

Covanis A, Gupta AK, Jeavons PM (1982) Sodium valproate: monotherapy and polytherapy. Epilepsia 23(6):693–720CrossRefPubMed

Motte J et al (1997) Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. Lamictal Lennox–Gastaut Study Group. N Engl J Med 337(25): 1807-1812CrossRefPubMed

Sachdeo RC et al (1999) A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Topiramate YL Study Group. Neurology 52(9):1882–1887CrossRefPubMed

Kim HJ et al (2014) Adjunctive levetiracetam treatment in pediatric Lennox–Gastaut syndrome. Pediatr Neurol 51(4):527–531CrossRefPubMed

Conry JA et al (2014) Stable dosages of clobazam for Lennox–Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia 55(4):558–567CrossRefPubMedPubMedCentral

10.

Isojarvi J et al (2016) Clobazam-treated patients with Lennox–Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia 57(6):e113–e116CrossRefPubMedPubMedCentral

11.

Isojarvi J et al (2018) Optimizing clobazam treatment in patients with Lennox–Gastaut syndrome. Epilepsy Behav 78:149–154CrossRefPubMed

12.

Sankar R et al (2014) Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series. J Med Case Rep 8:429CrossRefPubMedPubMedCentral

13.

Vassella F et al (1973) Treatment of infantile spasms and Lennox–Gastaut syndrome with clonazepam (Rivotril). Epilepsia 14(2):165–175CrossRefPubMed

14.

Glauser T et al (2008) Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology 70(21):1950–1958CrossRefPubMed

15.

You SJ et al (2008) Clinical efficacy of zonisamide in Lennox–Gastaut syndrome: Korean multicentric experience. Brain Dev 30(4):287–290CrossRefPubMed

16.

Felbamate Study Group in Lennox–Gastaut, S (1993) Efficacy of felbamate in childhood epileptic encephalopathy (Lennox–Gastaut syndrome). N Engl J Med 328(1): 29–33CrossRef

17.

Caraballo RH et al (2018) Sulthiame add-on therapy in children with Lennox–Gastaut syndrome: a study of 44 patients. Seizure 62:55–58CrossRefPubMed

18.

Devinsky O et al (2016) Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15(3):270–278CrossRefPubMed

19.

Geffrey AL et al (2015) Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 56(8):1246–1251CrossRefPubMed

20.

GW Pharmaceutical Announces Positive Phase 3 Pivotal Study Results for Epidiolex®(cannabidiol) in the Treatment of Lennox–Gastaut Syndrome (2016) GW Pharmaceuticals website. https://www.gwpharm.com/about/news/gw-pharmaceuticals-announces-positive-phase-3-pivotal-trial-results-epidiolex. Accessed 9 Nov 2016

21.

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex®(cannabidiol) in the Treatment of Lennox–Gastaut Syndrome (2016) GW Pharmaceuticals website. http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-announces-second-positive-phase-3-pivotal-0. Accessed 9 Nov 2016

22.

Grosso S et al (2014) Efficacy and tolerability of add-on lacosamide in children with Lennox–Gastaut syndrome. Acta Neurol Scand 129(6):420–424CrossRefPubMed

23.

Andrade-Machado R et al (2015) Efficacy and tolerability of add-on Lacosamide treatment in adults with Lennox–Gastaut syndrome: an observational study. Seizure 33:81–87CrossRefPubMed

24.

Miskin C et al (2016) Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy. J Child Neurol 31(7):925–928CrossRefPubMed

25.

Auvin S et al (2017) Use of perampanel in children and adolescents with Lennox–Gastaut Syndrome. Epilepsy Behav 74:59–63CrossRefPubMed

26.

Steinhoff BJ et al (2014) First clinical experiences with perampanel–the Kork experience in 74 patients. Epilepsia 55(Suppl 1):16–18CrossRefPubMed

27.

Huber B, Schmid G (2017) A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment. Epilepsy Behav 66:74–79CrossRefPubMed

28.

Lagae L et al (2018) A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox–Gastaut syndrome. Epilepsia 59(10):1881–1888CrossRefPubMed

29.

Yamatogi Y et al (1979) Treatment of the Lennox syndrome with ACTH: a clinical and electroencephalographic study. Brain Dev 1(4):267–276CrossRefPubMed

30.

O'Regan ME, Brown JK (1998) Is ACTH a key to understanding anticonvulsant action? Dev Med Child Neurol 40(2):82–89CrossRefPubMed

31.

Sinclair DB (2003) Prednisone therapy in pediatric epilepsy. Pediatr Neurol 28(3):194–198CrossRefPubMed

32.

Gross-Tsur V et al (1993) Intravenous high-dose gammaglobulins for intractable childhood epilepsy. Acta Neurol Scand 88(3):204–209CrossRefPubMed

33.

Illum N et al (1990) Intravenous immunoglobulin: a single-blind trial in children with Lennox–Gastaut syndrome. Neuropediatrics 21(2):87–90CrossRefPubMed

34.

van Rijckevorsel-Harmant K, Delire M, Rucquoy-Ponsar M (1986) Treatment of idiopathic West and Lennox–Gastaut syndromes by intravenous administration of human polyvalent immunoglobulins. Eur Arch Psychiatry Neurol Sci 236(2):119–122CrossRefPubMed

35.

Caraballo RH et al (2014) Ketogenic diet in patients with Lennox–Gastaut syndrome. Seizure 23(9):751–755CrossRefPubMed

36.

Freeman JM et al (2009) A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia 50(2):322–325CrossRefPubMed

37.

Lemmon ME et al (2012) Efficacy of the ketogenic diet in Lennox–Gastaut syndrome: a retrospective review of one institution's experience and summary of the literature. Dev Med Child Neurol 54(5):464–468CrossRefPubMed

38.

Zhang Y et al (2016) Therapeutic effects of the ketogenic diet in children with Lennox–Gastaut syndrome. Epilepsy Res 128:176–180CrossRefPubMed

39.

Sharma S et al (2015) Use of the modified Atkins diet in Lennox Gastaut syndrome. J Child Neurol 30(5):576–579CrossRefPubMed

40.

Kossoff EH et al (2018) Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open 3(2):175–192CrossRefPubMedPubMedCentral

41.

Lee YJ et al (2010) Resective pediatric epilepsy surgery in Lennox–Gastaut syndrome. Pediatrics 125(1):e58–66CrossRefPubMed

42.

Liu SY et al (2012) Surgical treatment of patients with Lennox-Gastaut syndrome phenotype. Sci World J 2012:614263. https://doi.org/10.1100/2012/614263 CrossRef

43.

Rolston JD et al (2018) Multiple subpial transections for medically refractory epilepsy: a disaggregated review of patient-level data. Neurosurgery 82(5):613–620CrossRefPubMed

44.

Spencer SS et al (2002) Multiple subpial transection for intractable partial epilepsy: an international meta-analysis. Epilepsia 43(2):141–145CrossRefPubMed

45.

Cukiert A et al (2006) Extended, one-stage callosal section for treatment of refractory secondarily generalized epilepsy in patients with Lennox–Gastaut and Lennox-like syndromes. Epilepsia 47(2):371–374CrossRefPubMed

46.

Liang S et al (2014) Anterior corpus callosotomy in school-aged children with Lennox–Gastaut syndrome: a prospective study. Eur J Paediatr Neurol 18(6):670–676CrossRefPubMed

47.

Kwan SY et al (2000) Seizure outcome after corpus callosotomy: the Taiwan experience. Childs Nerv Syst 16(2):87–92CrossRefPubMed

48.

You SJ et al (2008) Comparison of corpus callosotomy and vagus nerve stimulation in children with Lennox–Gastaut syndrome. Brain Dev 30(3):195–199CrossRefPubMed

49.

Morris GL 3rd et al (2013) Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 81(16):1453–1459CrossRefPubMedPubMedCentral

50.

Cersosimo RO et al (2011) Vagus nerve stimulation: effectiveness and tolerability in 64 paediatric patients with refractory epilepsies. Epileptic Disord 13(4):382–388PubMed

51.

Cukiert A et al (2013) A prospective long-term study on the outcome after vagus nerve stimulation at maximally tolerated current intensity in a cohort of children with refractory secondary generalized epilepsy. Neuromodulation 16(6):551–556 (discussion 556)CrossRefPubMed

52.

Cukiert A et al (2013) Long-term outcome after callosotomy or vagus nerve stimulation in consecutive prospective cohorts of children with Lennox–Gastaut or Lennox-like syndrome and non-specific MRI findings. Seizure 22(5):396–400CrossRefPubMed

53.

Li MCH, Cook MJ (2018) Deep brain stimulation for drug-resistant epilepsy. Epilepsia 59(2):273–290CrossRefPubMed

54.

Fisher RS et al (1992) Placebo-controlled pilot study of centromedian thalamic stimulation in treatment of intractable seizures. Epilepsia 33(5):841–851CrossRefPubMed

55.

Velasco F et al (2000) Predictors in the treatment of difficult-to-control seizures by electrical stimulation of the centromedian thalamic nucleus. Neurosurgery 47(2):295–304 (discussion 304-5)CrossRefPubMed

56.

Son BC et al (2016) Clinical outcome of patients with deep brain stimulation of the centromedian thalamic nucleus for refractory epilepsy and location of the active contacts. Stereotact Funct Neurosurg 94(3):187–197CrossRefPubMed

57.

Auvichayapat N et al (2016) Transcranial direct current stimulation for treatment of childhood pharmacoresistant lennox–Gastaut syndrome: a pilot study. Front Neurol 7:66CrossRefPubMedPubMedCentral

Titel: Therapeutic approach to Lennox–Gastaut syndrome: a systematic review
verfasst von: Serena Borrelli
Riem El Tahry
Publikationsdatum: 08.07.2019
Verlag: Springer International Publishing
Erschienen in: Acta Neurologica Belgica / Ausgabe 3/2019
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-019-01185-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Sudden blindness and deafness disclosing meningeal carcinomatosis in non-small cell lung cancer

Widening phenotypic spectrum of GABBR2 mutation

Late onset necrotizing autoimmune myopathy 1 year after cessation of statin treatment

Subependymal giant cell astrocytoma: an unexpected finding during a forensic autopsy

Evaluation of optic nerve head changes with optic coherence tomography in patients with idiopathic intracranial hypertension